Understanding ALS: New therapeutic approaches

FEBS Journal

Volumn 280, Issue 17, 2013, Pages 4315-4322

  Musarò, Antonio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ALS associated genes; amyotrophic lateral sclerosis; complexity of ALS pathogenesis; growth factors; mutant SOD1 toxicity; neuromuscular disease; oxidative stress; skeletal muscle; stem cells; therapeutic approaches

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; RILUZOLE; SOMATOMEDIN;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL PROTOCOL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; HEREDITY; HUMAN; MOTONEURON; MOUSE; MUSCLE ATROPHY; MUSCLE STRENGTH; NONHUMAN; OXIDATIVE STRESS; PARALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

ALS-ASSOCIATED GENES; AMYOTROPHIC LATERAL SCLEROSIS; COMPLEXITY OF ALS PATHOGENESIS; GROWTH FACTORS; MUTANT SOD1 TOXICITY; NEUROMUSCULAR DISEASE; OXIDATIVE STRESS; SKELETAL MUSCLE; STEM CELLS; THERAPEUTIC APPROACHES;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIBODIES, MONOCLONAL; EXERCISE THERAPY; GENETIC THERAPY; HUMANS;

EID: 84882637573     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12087     Document Type: Review

References (71)

1. Musarò A, (2010) State of the art and the dark side of amyotrophic lateral sclerosis. World J Biol Chem 1, 62-68.
2. Pasinelli P, &, Brown RH, (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7, 710-723.
3. Figlewicz DA, &, Orrell RW, (2003) The genetics of motor neuron diseases. Amyotroph Lateral Scler Other Motor Neuron Disord 4, 225-231.
4. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al,. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
5. Bruijn LI, Miller TM, &, Cleveland DW, (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27, 723-749.
6. Boillée S, Vande Velde C, &, Cleveland DW, (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39-59.
7. Gonzalez de Aguilar JL, Echaniz-Laguna A, Fergani A, René F, Meininger V, Loeffler JP, &, Dupuis L, (2007) Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem 101, 1153-1160.
8. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al,. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775.
9. Ripps ME, Huntley GW, Hof PR, Morrison JH, &, Gordon JW, (1995) Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 92, 689-693.
10. Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, et al,. (2001) The gene encoding alsin, a protein with three guaninenucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29, 160-165.
11. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, et al,. (2001) A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 29, 166-173.
12. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, Kok F, Oliveira JR, Gillingwater T, Webb J, et al,. (2004) A mutation in the vesicle trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75, 822-831.
13. Chance PF, (1998) Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 62, 633-640.
14. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, Dierick I, Abel A, Kennerson ML, Rabin BA, et al,. (2004) DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 74, 1128-1135.
15. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, et al,. (2003) Mutant dynactin in motor neuron disease. Nat Genet 33, 455-456.
16. Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al,. (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
17. Wegorzewska I, Bell S, Cairns NJ, Miller TM, &, Baloh RH, (2009) TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 106, 18809-18814.
18. Lagier-Tourenne C, &, Cleveland DW, (2009) Rethinking ALS: the FUS about TDP-43. Cell 136, 1001-1004.
19. Salajegheh M, Pinkus JL, Taylor JP, Amato AA, Nazareno R, Baloh RH, &, Greenberg SA, (2009) Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 40, 19-31.
20. Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R, et al,. (2010) FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 67, 739-748.
21. Lanson NA Jr, &, Pandey UB, (2012) FUS-related proteinopathies: lessons from animal models. Brain Res 1462, 44-60.
22. Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, Lowe P, Koppers M, McKenna-Yasek D, Baron DM, et al,. (2012) Mutations in the profiling 1 gene cause familial amyotrophic lateral sclerosis. Nature 488, 499-503.
23. Trotti D, Rolfs A, Danbolt NC, Brown RH Jr, &, Hediger MA, (1999) SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 2, 427-433.
24. Heath PR, &, Shaw PJ, (2002) Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26, 438-458.
25. Van Damme P, Dewil M, Robberecht W, &, Van Den Bosch L, (2005) Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2, 147-159.
26. Musarò A, Fulle S, &, Fanò G, (2010) Oxidative stress and muscle homeostasis. Curr Opin Clin Nutr Metab Care 13, 236-242.
27. Shaw PJ, Ince PG, Falkous G, &, Mantle D, (1995) Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 38, 691-695.
28. Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S, &, Kobayashi M, (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917, 97-104.
29. Fitzmaurice PS, Shaw IC, Kleiner HE, Miller RT, Monks TJ, Lau SS, Mitchell JD, &, Lynch PG, (1996) Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve 19, 797-798.
30. Rao SD, &, Weiss JH, (2004) Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci 27, 17-23.
31. Duffy LM, Chapman AL, Shaw PJ, &, Grierson AJ, (2011) The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 37, 336-352.
32. Wood JD, Beaujeux TP, &, Shaw PJ, (2003) Protein aggregation in motor neurone disorders. Neuropathol Appl Neurobiol 29, 529-545.
33. Kawamata H, &, Manfredi G, (2010) Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech Ageing Dev 131, 517-526.
34. G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 4, 16.
35. Higgins CM, Jung C, Ding H, &, Xu Z, (2002) Mutant Cu,Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci 22, RC215.
36. Takeuchi H, Kobayashi Y, Ishigaki S, Doyu M, &, Sobue G, (2002) Mitochondrial localization of mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of familial amyotrophic lateral sclerosis. J Biol Chem 277, 50966-50972.
37. Kawamata H, &, Manfredi G, (2008) Different regulation of wild-type and mutant Cu,Zn superoxide dismutase localization in mammalian mitochondria. Hum Mol Genet 17, 3303-3317.
38. Vande Velde C, Miller TM, Cashman NR, &, Cleveland DW, (2008) Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci USA 105, 4022-4027.
39. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, &, Gitler AD, (2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284, 20329-20339.
40. Kabashi E, &, Durham HD, (2006) Failure of protein quality control in amyotrophic lateral sclerosis. Biochim Biophys Acta 1762, 1038-1050.
41. Miller RG, Mitchell JD, &, Moore DH, (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 3, CD001447.
42. Gould TW, &, Oppenheim RW, (2011) Motor neuron trophic factors: therapeutic use in ALS? Brain Res Rev 67, 1-39.
43. Lanka V, Cudkowicz M, (2008) Therapy development for ALS: lessons learned and path forward. Amyotroph Lateral Scler 9, 131-140.
44. Beghi E, Chiò A, Couratier P, Esteban J, Hardiman O, Logroscino G, Millul A, Mitchell D, Preux PM, Pupillo E, et al,. (2011) The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 12, 1-10.
45. Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, &, Rosenthal N, (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27, 195-200.
46. Scicchitano BM, Rizzuto E, &, Musarò A, (2009) Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1. Aging 1, 451-457.
47. Kaspar BK, Lladõ J, Sherkat N, Rothstein JD, &, Gage FH, (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839-842.
48. Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, Molinaro M, Rosenthal N, &, Musarò A, (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168, 193-199.
49. Sakowski SA, Schuyler AD, &, Feldman EL, (2009) Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10, 63-73.
50. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, &, Rudnicki SA, (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. Neurology 49, 1621-1630.
51. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, Silani V, Vos PE, Wokke JH, &, Dobbins T, (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology 51, 583-586.
52. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, et al,. (2008) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71, 1770-1775.
53. Shavlakadze T, Winn N, Rosenthal N, &, Grounds MD, (2005) Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 15, 4-18.
54. Barton ER, (2006) The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Appl Physiol Nutr Metab 31, 791-797.
55. Boulis NM, Federici T, Glass JD, Lunn JS, Sakowski SA, &, Feldman EL, (2011) Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol 8, 172-176.
56. Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C, Pastore I, Marasso R, &, Madon E, (2003) Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 4, 158-161.
57. Silani V, Calzarossa C, Cova L, &, Ticozzi N, (2010) Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement? CNS Neurol Disord Drug Targets 9, 314-324.
58. Takahashi K, &, Yamanaka S, (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
59. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, et al,. (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218-1221.
60. Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA, &, Svendsen CN, (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280.
61. Karumbayaram S, Novitch BG, Patterson M, Umbach JA, Richter L, Lindgren A, Conway AE, Clark AT, Goldman SA, Plath K, et al,. (2009) Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 27, 806-811.
62. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillée S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, et al,. (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302, 113-117.
63. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, &, Cleveland DW, (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392.
64. Julien JP, (2007) ALS: astrocytes move in as deadly neighbors. Nat Neurosci 10, 535-537.
65. G93A-mediated toxicity. Cell Metab 8, 425-436.
66. Wong M, &, Martin LJ, (2010) Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet 19, 2284-2302.
67. Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Eschbach J, Rene F, Oudart H, Halter B, Huze C, Schaeffer L, Bouillaud F, et al,. (2009) Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS ONE 4, e5390.
68. Zhou J, Yi J, Fu R, Liu E, Siddique T, Ríos E, &, Deng HX, (2010) Hyperactive intracellular calcium signaling associated with localized mitochondrial defects in skeletal muscle of an animal model of amyotrophic lateral sclerosis. J Biol Chem 285, 705-712.
69. Miller TM, Kim SH, Yamanaka K, Hester M, Umapathi P, Arnson H, Rizo L, Mendell JR, Gage FH, Cleveland DW, et al,. (2006) Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 103, 19546-19551.
70. Da Cruz S, Parone PA, Lopes VS, Lillo C, McAlonis-Downes M, Lee SK, Vetto AP, Petrosyan S, Marsala M, Murphy AN, et al,. (2012) Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab 15, 778-786.
71. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, Mead R, Niessen HG, Petri S, Pradat PF, et al,. (2010) Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler 11, 38-45.